YM BioSciences Gets FDA Nod
Stock quotes in this article:
YMI
YM BioSciences(YMI Quote) rose higher in post-close trading Thursday on news that the Food and Drug Administration cleared the company to initiate a phase II trial on nimotuzumab for treatment of inoperable, treatment-resistant brain cancer in children.
The Canada-based company's development-stage program for nimotuzumab also includes trials in Canada, Europe, Japan, Korea, Singapore, India, Argentina and Brazil. Shares of the micro-cap company closed Thursday's regular session down 6 cents, or 3.7%, at $1.56, but rose 21 cents, or 13.5%, to $1.77 in post-close trading.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,452.00 | 1,107.93 | 2,201.05 | 36.03 |
Oil *
72.96
|
|
DOWN
49.05
|
DOWN
6.18
|
DOWN
11.05
|
UP
0.57
|
10 Yr
3.60%
SPDR Gold
110.21
|
|
-0.47%
|
-0.55%
|
-0.50%
|
+1.61%
|
Data delayed 20 minutes |
